Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province
10.3971/j.issn.1000-8578.2025.24.0856
- VernacularTitle:河北省晚期食管鳞癌免疫治疗现状及进展
- Author:
Xiaoyang DUAN
1
;
Jian SHI
1
Author Information
1. Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Esophageal squamous cell carcinoma;
Immunotherapy;
Research progress
- From:
Cancer Research on Prevention and Treatment
2025;52(2):103-109
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent gastrointestinal cancers in Hebei province. Most patients are diagnosed at an advanced stage due to untypical early symptoms, making surgical treatment often unfeasible. As a result, most of them are treated with comprehensive medical treatment, which tends to have limited effectiveness and poor prognosis. However, the recent introduction of immunotherapy has considerably advanced treatment options for patients with advanced ESCC, notably improving their prognosis. Uncertainties regarding immune resistance, the selection of predictive indicators of efficacy, the identification of dominant population, and the choice of combined treatment strategies are still evident. Therefore, based on the high incidence and poor prognosis of ESCC in Hebei Province, this article will briefly review the research progress in the treatment of advanced ESCC, aiming to provide guidance for treatment strategies for advanced esophageal cancer.
